SASS-001
- Generic Name
- SASS-001
NeuroTherapia and Sinaptica Advance Alzheimer's Therapies into Phase 2 Trials
• NeuroTherapia's NTRX-07, an oral neuroinflammatory inhibitor, receives EMA approval for a Phase 2 trial in Alzheimer's disease, aiming to improve neuronal function.
• Sinaptica Therapeutics initiates a Phase 2 trial for its second-generation SinaptiStim® system, combining rTMS and transcranial alternating current stimulation for early Alzheimer's.
• Sinaptica's dual stimulation technology shows potential for enhanced efficacy and reduced treatment time, building on positive Phase 1 data in healthy volunteers.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath